Recent developments in geriatric psychopharmacology

References

• Hybels C, Blazer D. Demography and Epidemiology of Psychiatric Disorders in Late Life. In: Steffens DC, Blazer DG, Thakur ME, editors. The American Psychiatric Publishing Textbook of Geriatric Psychiatry. Washington, DC: American Psychiatric Publishing; 2015. p. 3.
   Google Scholar
• United Nations. Ageing. https://www.un.org/en/sections/issues-depth/ageing/( Accessed 2020October22).
   Google Scholar
• Blazer D, Le M, Maslow K, et al. The mental health and substance use workforce for older adults: in whose hands? National Washington, DC: Academies Press; 2012.
   Google Scholar
• Tolar M, Abushakra S, Hey JA, et al. Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval. Alzheimer’s Res Ther. 2020;12(1):1–10.
   Web of Science ®Google Scholar
• Howard R, Liu KY. Questions emerge as biogen claims aducanumab turnaround. Nat Rev Neurol. 2020;16(2):63–64.
   PubMed Web of Science ®Google Scholar
• Schneider L. A resurrection of aducanumab for Alzheimer’s disease. Lancet Neurol. 2020;19(2):111–112.
   PubMed Web of Science ®Google Scholar
• Biogen. FDA accepts biogen’s aducanumab biologics license application. https://investors.biogen.com/news-releases/news-release-details/fda-accepts-biogens-aducanumab-biologics-license-application ( Accessed 2020October22).
   Google Scholar
• Fillit H, Green A. Aducanumab and the FDA - where are we now? Nat Rev Neurol. 2021. DOI:10.1038/s41582-020-00454-9
   PubMed Web of Science ®Google Scholar
• FDA statistical review and evaluation of Aducanumab. Pages 255–256. https://www.fda.gov/media/143502/download ( accessed 2020Nov5).
   Google Scholar
• Biogen’s aducanumab fails to win FDA panel backing. 2020Nov06. https://www.newsbreak.com/news/2097662704738/biogens-aducanumab-fails-to-win-fda-panel-backing (accessed 11/6/2020).).
   Google Scholar
• Logovinsky V, Satlin A, Lai R, et al. Safety and tolerability of BAN2401-a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody. Alzheimer’s Res Ther. 2016;8(1):14. .
   PubMedGoogle Scholar
• Klein G, Delmar P, Voyle N, et al. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis. Alzheimer’s Res Ther. 2019;11(1):101. .
   PubMed Web of Science ®Google Scholar
• Manzano S, Agüera L, Aguilar M, et al. Review on tramiprosate (Homotaurine) in Alzheimer’s disease and other neurocognitive disorders. Front Neurol. 2020;11(614). DOI:10.3389/fneur.2020.00614
   PubMedGoogle Scholar
• Abushakra S, Porsteinsson A, Vellas B, et al. Clinical benefits of tramiprosate in Alzheimer’s disease are associated with higher number of APOE4 alleles: the “APOE4 gene-dose effect”. J Prev Alzheimers Dis. 2016;3(4):219–228.
   PubMedGoogle Scholar
• Alzheon. ALZ-801. https://alzheon.com/pipeline/alzheon-alz-801/( accessed 2020October22).
   Google Scholar
• Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2018;14(7):399–415.
   PubMed Web of Science ®Google Scholar
• Suppiah S, Didier M-A VS. The who, when, why, and how of PET amyloid imaging in management of Alzheimer’s disease—review of literature and interesting images. Diagnostics. 2019;9(2):65.
   Web of Science ®Google Scholar
• FDA. Amyvid: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202008s036lbl.pdf ( Accessed 2020October22).
   Google Scholar
• Yeo JM, Waddell B, Khan Z, et al. A systematic review and meta-analysis of 18F-labeled amyloid imaging in Alzheimer’s disease. Alzheimers Dement. 2015;1(1):5–13.
   Google Scholar
• Mallik A, Drzezga A, Minoshima S. Clinical Amyloid Imaging. Semin Nucl Med. 2017;47:31–43.
   Google Scholar
• Apostolova LG, Haider JM, Goukasian N, et al. Critical review of the appropriate use criteria for amyloid imaging: effect on diagnosis and patient care. Alzheimers Dement. 2016;5:15–22.
   Google Scholar
• CMS. Amyloid PET. https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/Amyloid-PET ( accessed 2020October22).
   Google Scholar
• FDA. Tauvid. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212123s000lbl.pdf ( accessed 2020October22).
   Google Scholar
• Fleisher AS, Pontecorvo MJ, Devous MD, et al. Positron emission tomography imaging with [18F] flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes.. JAMA Neurol. 2020; doi:10.1001/jamaneurol.2020.0528.
   PubMed Web of Science ®Google Scholar
• Bessey LJ, Walaszek A. Management of behavioral and psychological symptoms of dementia. Curr Psychiatry Rep. 2019;21(8):66.
   PubMed Web of Science ®Google Scholar
• Tampi RR, Tampi DJ, Balachandran S, et al. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229–245.
   PubMed Web of Science ®Google Scholar
• Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. Jama. 2011;306(12):1359–1369. .
   PubMed Web of Science ®Google Scholar
• Hacksell U, Burstein ES, McFarland K, et al. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson’s psychosis. Neurochem Res. 2014;39(10):2008–2017.
   PubMed Web of Science ®Google Scholar
• Weiner DM, Burstein E, Nash N, et al. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther. 2001;299(1):268–276.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. CNS Spectr. 2016;21(4):271–275.
   PubMed Web of Science ®Google Scholar
• Ballard C, Banister C, Khan Z, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 2018;17(3):213–222.
   PubMed Web of Science ®Google Scholar
• Ralph SJ, Espinet AJ. Increased all-cause mortality by antipsychotic drugs: updated review and meta-analysis in dementia and general mental health care. J Alzheimer’s Dis Reports. 2018;2(1):1–26.
   PubMedGoogle Scholar
• Yunusa I, El Helou ML, Alsahali S. Pimavanserin: a novel antipsychotic with potentials to address an unmet need of older adults with dementia-related psychosis. Front Pharmacol. 2020;11(87). DOI:10.3389/fphar.2020.00087
   Google Scholar
• Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589–604.
   PubMed Web of Science ®Google Scholar
• Grossberg GT, Kohegyi E, Mergel V, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer’s dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatric Psychiatry. 2020;28(4):383–400.
   PubMed Web of Science ®Google Scholar
• Mos J, Olivier B, Poth M, et al. The effects of intraventricular administration of eltoprazine, 1-(3-trifluoromethylphenyl) piperazine hydrochloride and 8-hydroxy-2-(di-n-propylamino) tetralin on resident intruder aggression in the rat. Eur J Pharmacol. 1992;212(2–3):295–298.
   PubMed Web of Science ®Google Scholar
• Schipper J, Tulp MTM, Sijbesma H. Neurochemical profile of eltoprazine. Drug Metab Drug Interact. 1990;8(1–2):85–114.
   PubMedGoogle Scholar
• Svenningsson P, Rosenblad C. af Edholm Arvidsson K et al. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study. Brain. 2015;138(4):963–973.
   PubMedGoogle Scholar
• Tiihonen J, Hakola P, Paanila J, et al. Eltoprazine for aggression in schizophrenia and mental retardation. Lancet. 1993;341(8840):307.
   PubMed Web of Science ®Google Scholar
• Amarantus Bioscience Holdings. Amarantus announces positive phase 2 data for eltoprazine in Alzheimer’s Aggression. 2015Dec08. https://www.amarantus.com/news/press-releases/detail/2033/amarantus-announces-positive-phase-2-data-for-eltoprazine (Accessed 1/19/2021).
   Google Scholar
• Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682–691.
   PubMed Web of Science ®Google Scholar
• Barak Y, Plopski I, Tadger S, et al. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer’s disease: a randomized double-blind pilot study. Int Psychogeriatr. 2011;23(9):1515–1519.
   PubMed Web of Science ®Google Scholar
• Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatric Psychiatry. 2007;15(11):942–952. .
   PubMed Web of Science ®Google Scholar
• Cakir S, Kulaksizoglu IB. The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: a 12-week open-label pilot study. Neuropsychiatr Dis Treat. 2008;4(5):963.
   PubMedGoogle Scholar
• Taylor CP, Traynelis SF, Siffert J, et al. Pharmacology of dextromethorphan: relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. Pharmacol Ther. 2016;164(170–182). DOI:10.1016/j.pharmthera.2016.04.010
   PubMedGoogle Scholar
• Morris H, Wallach J. From PCP to MXE: a comprehensive review of the non‐medical use of dissociative drugs. Drug Test Anal. 2014;6(7–8):614–632.
   PubMed Web of Science ®Google Scholar
• Garay RP, Grossberg GT. AVP-786 for the treatment of agitation in dementia of the Alzheimer’s type. Expert Opin Investig Drugs. 2017;26(1):121–132.
   PubMed Web of Science ®Google Scholar
• Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. Jama. 2015;314(12):1242–1254.
   PubMed Web of Science ®Google Scholar
• Dwoskin LP, Rauhut AS, King‐Pospisil KA, et al. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev. 2006;12(3‐4):178–207.
   PubMedGoogle Scholar
• Ruthirakuhan MT, Herrmann N, Abraham EH, et al. Pharmacological interventions for apathy in Alzheimer’s disease. Cochrane Database Syst Rev. 2018;5(5):CD012197.
   Google Scholar
• Padala PR, Padala KP, Lensing SY, et al. Methylphenidate for apathy in community-dwelling older veterans with mild Alzheimer’s disease: a double-blind, randomized, placebo-controlled trial. Am J Psychiatry. 2018;175(2):159–168. .
   PubMed Web of Science ®Google Scholar
• Nardell M, Tampi RR. Pharmacological treatments for frontotemporal dementias: a systematic review of randomized controlled trials. Am J Alzheimer’s Dis Other Dementias®. 2014;29(2):123–132.
   PubMed Web of Science ®Google Scholar
• Scherer RW, Drye L, Mintzer J, et al. The apathy in dementia methylphenidate trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018;19(1):46. .
   PubMedGoogle Scholar
• Devanand DP, Pelton GH, D’Antonio K, et al. Low-dose Lithium treatment for agitation and psychosis in Alzheimer’s disease and Frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord. 2017;31(1):73. .
   PubMed Web of Science ®Google Scholar
• Devanand DP, Strickler JG, Huey ED, et al. Lithium treatment for agitation in Alzheimer’s disease (Lit-AD): clinical rationale and study design. Contemp Clin Trials. 2018;71(33–39). DOI:10.1016/j.cct.2018.05.019.
   PubMedGoogle Scholar
• Blytt KM, Bjorvatn B, Husebo B, et al. Clinically significant discrepancies between sleep problems assessed by standard clinical tools and actigraphy. BMC Geriatr. 2017;17(1):253.
   PubMedGoogle Scholar
• Roane DM, Feinberg TE, Meckler L, et al. Treatment of dementia-associated agitation with gabapentin. J Neuropsychiatry Clin Neurosci. 2000;12(1):40–43.
   PubMed Web of Science ®Google Scholar
• Kim Y, Wilkins KM, Tampi RR. Use of gabapentin in the treatment of behavioural and psychological symptoms of dementia. Drugs Aging. 2008;25(3):187–196.
   PubMed Web of Science ®Google Scholar
• Buskova J, Busek P, Nevsimalova S. Gabapentin in the treatment of dementia-associated nocturnal agitation. Med Sci Monit. 2011;17(12):CS149.
   PubMed Web of Science ®Google Scholar
• Sammaritano M, Sherwin A. Effect of anticonvulsants on sleep. Neurology. 2000;54(5 Suppl 1):S16-24.
   PubMed Web of Science ®Google Scholar
• Chouinard G, Beauclair L, Belanger M. Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry. 1998;43(3):305.
   PubMed Web of Science ®Google Scholar
• Szot P, White SS, Greenup JL, et al. Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes. Neuroscience. 2007;146(1):471–480.
   PubMed Web of Science ®Google Scholar
• Szot P, White SS, Greenup JL, et al. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer’s disease and dementia with Lewy bodies. J Neurosci. 2006;26(2):467–478.
   PubMed Web of Science ®Google Scholar
• Sharp SI, Ballard CG, Chen CP-H, et al. Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease. Am J Geriatric Psychiatry. 2007;15(5):435–437.
   PubMed Web of Science ®Google Scholar
• Wang LY, Shofer JB, Rohde K, et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatric Psychiatry. 2009;17(9):744–751.
   PubMed Web of Science ®Google Scholar
• Greve MJ, DesJarlais D, Ahmed I. Successful treatment of agitation and aggression with prazosin in an elderly patient with dementia and comorbid heart disease. J Clin Gerontol Geriatrics. 2016;7(3):109–111.
   Web of Science ®Google Scholar
• Van Zwieten P. Antihypertensive drugs interacting with α-and β-adrenoceptors. Drugs. 1988;35(Supplement6):6–19.
   PubMedGoogle Scholar
• Han Y, Chen J, Zou D, et al. Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatr Dis Treat. 2016;12(2859). DOI:10.2147/NDT.S117146.
   Google Scholar
• da Frota Ribeiro CM, Riva-Posse P. Use of ketamine in elderly patients with treatment-resistant depression. Curr Psychiatry Rep. 2017;19(12):107.
   PubMed Web of Science ®Google Scholar
• Bryant KA, Altinay M, Finnegan N, et al. Effects of repeated intravenous ketamine in treatment-resistant geriatric depression: a case series. J Clin Psychopharmacol. 2019;39(2):158–161.
   PubMed Web of Science ®Google Scholar
• Szymkowicz SM, Finnegan N, Dale RM. Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder. J Clin Psychopharmacol. 2014;34(2):285.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Gangwar R, Kumar A. Safety and efficacy of ketamine infusion in late onset depression, and conversion to treatment response. Indian J Psychiatry. 2015;57(3). DOI:10.4103/0019-5545.166627
   Web of Science ®Google Scholar
• George D, Gálvez V, Martin D, et al. Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression. Am J Geriatric Psychiatry. 2017;25(11):1199–1209.
   PubMed Web of Science ®Google Scholar
• Short B, Fong J, Galvez V, et al. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5(1):65–78.
   PubMed Web of Science ®Google Scholar
• Ochs-Ross R, Daly EJ, Zhang Y, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression—TRANSFORM-3.Am J Geriatric Psychiatry. 2020;28(2):121–141.
   PubMed Web of Science ®Google Scholar
• Bahr R, Lopez A, Rey JA. Intranasal Esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant. Pharm Ther. 2019;44(6):340.
   Google Scholar
• Johnson MW, Hendricks PS, Barrett FS, et al. Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. 2019;197:83–102.
   PubMedGoogle Scholar
• Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Ther. 2017;101(2):209–219.
   PubMed Web of Science ®Google Scholar
• Breeksema JJ, Niemeijer AR, Krediet E, et al. Psychedelic treatments for psychiatric disorders: a systematic review and thematic synthesis of patient experiences in qualitative studies. CNS Drugs. 2020;1-22.
   Google Scholar
• Krebs TS, Johansen P-Ø Over 30 million psychedelic users in the United States. F1000Research, 2 (2013).
   Google Scholar
• Dos Santos RG, Bouso JC, MÁ A-C, et al. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert Rev Clin Pharmacol. 2018;11(9):889–902.
   PubMed Web of Science ®Google Scholar
• Family N, Maillet EL, Williams LT, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology (Berl). 2020;237(3):841–853. .
   PubMed Web of Science ®Google Scholar
• Bahji A, Forsyth A, Groll D, et al. Efficacy of 3, 4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: a systematic review and meta-analysis. Prog Neuro Psychopharmacol Biol Psychiatry. 2020;96:109735.
   PubMed Web of Science ®Google Scholar
• Romeo B, Karila L, Martelli C, et al. Efficacy of psychedelic treatments on depressive symptoms: a meta-analysis. J Psychopharmacol. 0269881120919957. 2020; 10doi:10.1177/0269881120919957
   Google Scholar
• Bogenschutz MP, Johnson MW. Classic hallucinogens in the treatment of addictions. Prog Neuro Psychopharmacol Biol Psychiatry. 2016;64(250). DOI:10.1016/j.pnpbp.2015.03.002
   PubMedGoogle Scholar
• Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160–174. .
   PubMed Web of Science ®Google Scholar
• Reiche S, Hermle L, Gutwinski S, et al. Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: a systematic review. Prog Neuro Psychopharmacol Biol Psychiatry. 2018;81(1). DOI:10.1016/j.pnpbp.2017.09.012
   PubMedGoogle Scholar
• Ross S. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int Rev Psychiatry. 2018;30(4):317–330.
   PubMed Web of Science ®Google Scholar
• Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202(7):513.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–1197.
   PubMed Web of Science ®Google Scholar
• Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71–78.
   PubMed Web of Science ®Google Scholar
• Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–1180.
   PubMed Web of Science ®Google Scholar
• Aday JS, Bloesch EK, Davoli CC. Can psychedelic drugs attenuate age-related changes in cognition and affect? J Cognit Enhancement. 2020;4;219–227.
   Google Scholar
• Lafaye G, Karila L, Blecha L, et al. Cannabis, cannabinoids, and health. Dialogues Clin Neurosci. 2017;19(3):309.
   PubMed Web of Science ®Google Scholar
• Häuser W, Finn DP, Kalso E, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis‐based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018;22(9):1547–1564. .
   PubMed Web of Science ®Google Scholar
• Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. Pharm Ther. 2017;42(3):180.
   Google Scholar
• Han BH, Palamar JJ. Trends in cannabis use among older adults in the United States, 2015-2018. JAMA Intern Med. 2020;180(4):609–611.
   PubMed Web of Science ®Google Scholar
• Klumpers LE, Thacker DL. A brief background on cannabis: from plant to medical indications. J AOAC Int. 2019;102(2):412–420.
   PubMed Web of Science ®Google Scholar
• Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995–1010.
   PubMed Web of Science ®Google Scholar
• Beedham W, Sbai M, Allison I, et al. Cannabinoids in the older person: a literature review. Geriatrics. 2020;5(1):2.
   Web of Science ®Google Scholar
• Minerbi A, Häuser W, Fitzcharles M-A. Medical cannabis for older patients. Drugs Aging. 2019;36(1):39–51.
   PubMed Web of Science ®Google Scholar
• van den Elsen GA, Ahmed AI, Lammers M, et al. Efficacy and safety of medical cannabinoids in older subjects: a systematic review. Ageing Res Rev. 2014;14(56–64). DOI:10.1016/j.arr.2014.01.007.
   PubMedGoogle Scholar
• Abuhasira R, Ron A, Sikorin I, et al. Medical cannabis for older patients—treatment protocol and initial results. J Clin Med. 2019;8(11):1819.
   Web of Science ®Google Scholar
• Liu CS, Chau SA, Ruthirakuhan M, et al. Cannabinoids for the treatment of agitation and aggression in Alzheimer’s disease. CNS Drugs. 2015;29(8):615–623.
   PubMed Web of Science ®Google Scholar
• Bahji A, Meyyappan AC, Hawken ER. Cannabinoids for the neuropsychiatric symptoms of dementia: a systematic review and meta-analysis. Can J Psychiatry. 2020;65(6):365–376.
   PubMed Web of Science ®Google Scholar
• Hillen JB, Soulsby N, Alderman C, et al., Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: a systematic review. Ther Adv Drug Saf. 10: 2042098619846993. 2019; doi:10.1177/2042098619846993.
   PubMed Web of Science ®Google Scholar
• Paunescu H, Dima L, Ghita I, et al. A systematic review of clinical studies on the effect of psychoactive cannabinoids in psychiatric conditions in Alzheimer Dementia. Am J Ther. 2020;27(3):e249–e269.
   PubMed Web of Science ®Google Scholar
• Bougea A, Koros C, Simitsi AM, et al., Medical cannabis as an alternative therapeutics for Parkinsons’ disease: systematic review. Complement Ther Clin Pract. 39: 101154. 2020; doi:10.1016/j.ctcp.2020.101154.
   PubMed Web of Science ®Google Scholar
• van den Elsen GA, Tobben L, Ahmed AI, et al. Effects of tetrahydrocannabinol on balance and gait in patients with dementia: a randomised controlled crossover trial. J Psychopharmacol. 2017;31(2):184–191.
   PubMed Web of Science ®Google Scholar
• Ahmed AI, van den Elsen GA, Colbers A, et al. Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Psychopharmacology (Berl). 2015;232(14):2587–2595. .
   PubMed Web of Science ®Google Scholar
• van den Elsen GA, Ahmed AI, Verkes R-J, et al. Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized controlled trial. Am J Geriatric Psychiatry. 2015;23(12):1214–1224.
   PubMed Web of Science ®Google Scholar
• Van Den Elsen GA, Ahmed AI, Verkes R. J et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. Neurology. 2015;84(23):2338–2346.
   PubMed Web of Science ®Google Scholar
• Walther S, Schüpbach B, Seifritz E, et al. Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia. J Clin Psychopharmacol. 2011;31(2):256–258.
   PubMed Web of Science ®Google Scholar
• Walther S, Mahlberg R, Eichmann U, et al. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl). 2006;185(4):524–528.
   PubMed Web of Science ®Google Scholar
• Volicer L, Stelly M, Morris J, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 1997;12(9):913–919.
   PubMed Web of Science ®Google Scholar
• Herrmann N, Ruthirakuhan M, Gallagher D, et al. Randomized placebo-controlled trial of nabilone for agitation in Alzheimer’s disease. Am J Geriatric Psychiatry. 2019;27(11):1161–1173.
   PubMed Web of Science ®Google Scholar
• Lanctot KL, Ruthirakuhan M, Gallagher D, et al. Nabilone significantly improves agitation/aggression in patients with moderate-to-severe AD: preliminary results of a placebo-controlled, double-blind, cross-over trial. Alzheimers Dement. 2018;14(7):p1385.
   Google Scholar
• Carroll C, Bain P, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology. 2004;63(7):1245–1250.
   PubMed Web of Science ®Google Scholar
• Mesnage V, Houeto J, Bonnet A, et al. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol. 2004;27(3):108–110.
   PubMed Web of Science ®Google Scholar
• Sieradzan K, Fox S, Hill M, et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study. Neurology. 2001;57(11):2108–2111.
   PubMed Web of Science ®Google Scholar
• Chagas MHN, Zuardi AW, Tumas V, et al. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J Psychopharmacol. 2014;28(11):1088–1098.
   PubMed Web of Science ®Google Scholar
• de Faria SM, de Morais Fabrício D, Tumas V, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a simulated Public Speaking Test in patients with Parkinson’s disease. J Psychopharmacol. 2020;34(2):189–196.
   PubMed Web of Science ®Google Scholar
• Chagas MH, Eckeli A, Zuardi AW, et al. Cannabidiol can improve complex sleep‐related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther. 2014;39(5):564–566.
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Crippa J, Hallak J, et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol. 2009;23(8):979–983.
   PubMed Web of Science ®Google Scholar
• Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011;5(1):1.
   PubMed Web of Science ®Google Scholar
• Dregan A, Gulliford MC. Is illicit drug use harmful to cognitive functioning in the midadult years? A cohort-based investigation. Am J Epidemiol. 2012;175(3):218–227.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Ganae-Motan ED. Allende S et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438–449.
   PubMed Web of Science ®Google Scholar
• Weber M, Goldman B, Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J Neurol Neurosurg. 2010;81(10):1135–1140.
   PubMed Web of Science ®Google Scholar
• Toth C, Mawani S, Brady S, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. PAIN®. 2012;153(10):2073–2082.
   PubMed Web of Science ®Google Scholar
• Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39(2):167–179.
   PubMed Web of Science ®Google Scholar
• Brisbois T, De Kock I, Watanabe S, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol. 2011;22(9):2086–2093.
   PubMed Web of Science ®Google Scholar
• Tolar M, Abushakra S, Sabbagh M. The path forward in Alzheimer’s disease therapeutics: reevaluating the amyloid cascade hypothesis. Alzheimers Dement. 2020;16(11):1553-1560.
   PubMed Web of Science ®Google Scholar
• Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer’s disease. Int J Biochem Cell Biol. 2009;41(6):1261–1268.
   PubMed Web of Science ®Google Scholar
• Gerlach LB, Kales HC. Pharmacological management of neuropsychiatric symptoms of Dementia. Curr Treat Options Psychiatry. 2020;7(4):489-507.
   PubMedGoogle Scholar
• Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? Bipolar Disord. 2010;12(1):87–94.
   PubMed Web of Science ®Google Scholar
• Schatzberg AF. A word to the wise about intranasal esketamine. Am J Psychiatry. 2019;176(6):422–424.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE).Nasal spray medicine for treatment-resistant depression not recommended by NICE.2020Jan28.https://www.nice.org.uk/news/article/nasal-spray-medicine-for-treatment-resistant-depression-not-recommended-by-nice (Accessed Nov 6, 2020)).
   Google Scholar